Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.

BRUSSELS, April 12 (Reuters) - U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after ...

BRUSSELS (Reuters) -U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the ...

BRUSSELS, April 12 (Reuters) - U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having ...

BRUSSELS (Reuters) -U.S. gene sequencing company Illumina (NASDAQ:ILMN)'s plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after ...